Life Sciences

Improving patient access and uptake of innovations with our industry-leading expertise

CF’s life sciences consulting research and data capabilities combines deep knowledge of health systems with unparalleled access to healthcare data. We support clients with an in-depth understanding of healthcare systems and patient pathways, market research, real world evidence, digital products and strategy to drive innovation uptake and performance. We have a deep understanding of different disease pathologies and pathways and worked extensively across multiple therapeutic areas, including cancer, neurology, cardiovascular diseases, and expertise in the field of genomics and longevity. We have pioneered a comprehensive 360° approach, supporting clients in enhancing the uptake of technologies, ultimately benefits patients everywhere.

Launching a pharmaceutical product can feel like forcing a square peg into a round hole, presenting its own set of challenges and opportunities. Understanding what it takes to achieve clinical adoption at scale is crucial. Many products fail to gain market uptake due to non-clinical barriers, such as lack of screening or financial disincentives. Benchmarking current market shaping capability within a therapeutic area across EMEA, well ahead of launch, is essential to navigate these complexities and ensure successful market entry.

Our approach

As a trusted partner to both health systems and the life sciences industry, CF supports pharma understand and navigate the path to innovation uptake. We facilitate productive partnerships between life sciences, government, health system partners, payors, and providers.

Our approach is highly collaborative and leverages our therapeutic area expertise and in-depth understanding of current pathways and processes, underpinned by healthcare system data. We work closely with clinicians, payors, health system stakeholders, patients, and regulators prior to launch, striving to align the needs of the health system with life sciences objectives. Our ultimate goal is to support rapid access to innovation and support the development of new services that improve patient outcomes and support sustainable healthcare.

Our offers

System shaping services

Our System Shaping services aim to support equitable access and the adoption of innovation within healthcare systems. We help pharmaceutical companies navigate new and existing therapeutic area pathways to improve outcomes by developing compelling clinical narratives and leveraging system levers.

Our offerings include:

Supporting equitable access and adoption of innovation.
Mapping and navigating therapeutic area pathways for access to innovation and service development.
Preparing health systems to receive and implement innovation across the entire pathway.
Utilizing a market shaping tool to help clients understand their current capabilities and identify areas for organizational improvement.

We work with life science companies to elucidate the uptake pathway, leveraging granular, patient-level data along with our access to clinicians to demonstrate burden of disease. Alternatively, for existing pathways, we support transformation through innovative redesigns, proposing ideal pathways and identification of barriers to uptake. This approach assists in successful implementation and decision-making for treatment maintenance, ensuring optimal outcomes.

Our services focus on key elements such as:

Clear articulation of the value proposition for patients, physicians, payors, providers, and the overall system.
Clinical advocacy, including identification and engagement of relevant clinical groups and Key Opinion Leaders.
Patient advocacy, including engagement with charities and groups.
Development and integration of clinical guidelines to understand where the product fits within the existing standard of care.

Data, digital, and AI services

We harness advanced analytics, digital solutions, and AI to solve complex healthcare challenges, turning data into actionable strategies that drive sustained improvements. As AI and digital technologies evolve, we help pharmaceutical companies, health systems, and payors optimize patient pathways. Our expertise ensures secure, compliant data strategies while navigating regulatory landscapes, balancing innovation with robust governance.

Our Data, Digital, and AI services focus on generating strategies and insights by leveraging data, health analytics tools, and AI. We aim to create value through digital transformation while ensuring data security.

Our offerings include:

Developing and implementing RWD, digital, and AI strategies.
Generating strategies and insights using data, health analytics tools, and AI.
Creating value through AI and digital strategies to help Pharma balance innovation and data security.
Crafting data, digital, and AI strategies with robust information governance and cybersecurity measures.
Developing tools and platforms to address complex multifactorial problems traditionally unsolvable.

Real-world evidence (RWE)

CF combines consultancy, award-winning data science, and research expertise to deliver meaningful evidence generation and data strategies. As a leading provider of non-interventional studies, we drive successful market access and innovation uptake. With growing demand for real-world evidence (RWE), we leverage patient-level data to refine go-to-market strategies while ensuring compliance with regulations, ethics, and data governance. Our multidisciplinary team uses advanced analytics to generate actionable insights on health outcomes, inequalities, and product adoption.

Our Real-World Evidence (RWE) services are designed to support regulatory submissions and enhance the feasibility of studies through synthetic control arms. We cater to the increasing demand from pharmaceutical companies to achieve approval and bring innovations to market.

Our offerings include:

Supporting regulatory submissions and synthetic control arms for feasibility studies.
Leveraging RWE for drug safety and efficacy to support the submission process or create synthetic data/control arms for simulations.
Managing RWE for one-arm observational studies and economic modelling.